Immunome (NASDAQ:IMNM) Director Sells $2,134,176.00 in Stock

by · The Cerbat Gem

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) Director Isaac Barchas sold 101,050 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00. Following the sale, the director owned 308,504 shares in the company, valued at $6,515,604.48. The trade was a 24.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

  • On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.

Immunome Price Performance

Shares of IMNM traded up $2.12 during midday trading on Thursday, hitting $23.61. The stock had a trading volume of 1,869,014 shares, compared to its average volume of 1,683,587. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65. The firm has a market cap of $2.67 billion, a PE ratio of -9.92 and a beta of 2.07. The stock’s 50 day moving average is $20.96 and its 200 day moving average is $21.78.

Immunome (NASDAQ:IMNM – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IMNM. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Immunome in a research note on Wednesday, May 13th. Stephens dropped their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Leerink Partners reduced their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Finally, Truist Financial increased their price objective on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Immunome presently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Get Our Latest Stock Report on Immunome

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. KBC Group NV acquired a new stake in Immunome during the 1st quarter worth $60,000. Strs Ohio bought a new stake in Immunome during the fourth quarter worth $64,000. Assetmark Inc. boosted its stake in Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after buying an additional 1,442 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in Immunome in the fourth quarter valued at about $121,000. Finally, BNP Paribas Financial Markets boosted its position in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

Recommended Stories